Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508)
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
🩺 Plain-English Summary (8th-Grade Level)
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.
Who can join: Review the eligibility criteria below.
Location: Cellectar Biosciences site — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- Cellectar Biosciences site — Los Angeles, California
- Cellectar Biosciences site — Redlands, California
- Cellectar Biosciences site — Washington D.C., District of Columbia
- Cellectar Biosciences site — Jacksonville, Florida
- Cellectar Biosciences site — Miami, Florida
- Cellectar Biosciences site — Tampa, Florida
- Cellectar Biosciences — Atlanta, Georgia
- Cellectar Biosciences site — Maywood, Illinois
- Cellectar Biosciences site — Warrenville, Illinois
- Cellectar Biosciences site — Westwood, Kansas
- Cellectar Biosciences site — New Orleans, Louisiana
- Cellectar Biosciences site — Baltimore, Maryland
- Cellectar Biosciences — Bethesda, Maryland
- Cellectar Biosciences site — Boston, Massachusetts
- Cellectar Biosciences — North Bergen, New Jersey
- Cellectar Biosciences site — Buffalo, New York
- Cellectar Biosciences site — New York, New York
- Cellectar Biosciences site — Rochester, New York
- Cellectar Biosciences site — Durham, North Carolina
- Cellectar Biosciences — Canton, Ohio
- Cellectar Biosciences site — Cincinnati, Ohio
- Cellectar Biosciences Site — Charleston, South Carolina
- Cellectar Biosciences — Greenville, South Carolina
- Cellectar Biosciences site — Knoxville, Tennessee
- Cellectar Biosciences site — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Waldenstrom Macroglobulinemia
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia — Boston, Massachusetts
- Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer — Bethesda, Maryland
- A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia — Duarte, California
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia — Calgary, Alberta
- Ibrutinib + Venetoclax in Untreated WM — Boston, Massachusetts
Explore by condition: All Waldenstrom Macroglobulinemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.